OBJECTIVES: The aim of the study was to assess whether subpopulations with sufficiently high HIV incidences for HIV prevention trials can be identified in low HIV incidence settings such as Australia. METHODS: In a community-based cohort study of HIV-negative homosexually active men in Sydney, Australia, potential risk factors associated with an annual HIV incidence of ≥2 per 100 person-years (PY) were identified. A stepwise procedure ranked these factors according to HIV incidence, to create a 'high-incidence' subgroup of participants. Willingness to participate in HIV prevention trials was assessed. RESULTS: Although the incidence in the cohort overall was only 0.78 per 100 PY, nine risk variables were associated with an HIV incidence of 2 per 100 PY or greater. Stepwise inclusion of these variables revealed a 'high-incidence' subgroup of men representing 24% of the total follow-up time with a combined HIV incidence of 2.71 per 100 PY, who reported at least one of three risk factors in the past 6 months. These men were more willing than others to participate in vaccine and antiretroviral therapy HIV prevention trials. CONCLUSIONS: These findings demonstrate that it is possible to identify high HIV incidence subpopulations in low-incidence settings such as Australia, and these men are of above average willingness to participate in HIV prevention trials.
OBJECTIVES: The aim of the study was to assess whether subpopulations with sufficiently high HIV incidences for HIV prevention trials can be identified in low HIV incidence settings such as Australia. METHODS: In a community-based cohort study of HIV-negative homosexually active men in Sydney, Australia, potential risk factors associated with an annual HIV incidence of ≥2 per 100 person-years (PY) were identified. A stepwise procedure ranked these factors according to HIV incidence, to create a 'high-incidence' subgroup of participants. Willingness to participate in HIV prevention trials was assessed. RESULTS: Although the incidence in the cohort overall was only 0.78 per 100 PY, nine risk variables were associated with an HIV incidence of 2 per 100 PY or greater. Stepwise inclusion of these variables revealed a 'high-incidence' subgroup of men representing 24% of the total follow-up time with a combined HIV incidence of 2.71 per 100 PY, who reported at least one of three risk factors in the past 6 months. These men were more willing than others to participate in vaccine and antiretroviral therapy HIV prevention trials. CONCLUSIONS: These findings demonstrate that it is possible to identify high HIV incidence subpopulations in low-incidence settings such as Australia, and these men are of above average willingness to participate in HIV prevention trials.
Authors: Damian P Conway; Rebecca Guy; Stephen C Davies; Deborah L Couldwell; Anna McNulty; Don E Smith; Phillip Keen; Philip Cunningham; Martin Holt Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Damian P Conway; Martin Holt; Anna McNulty; Deborah L Couldwell; Don E Smith; Stephen C Davies; Philip Cunningham; Phillip Keen; Rebecca Guy Journal: PLoS One Date: 2014-04-08 Impact factor: 3.240
Authors: Nicolas Lorente; Laura Fernàndez-López; Ricardo Fuertes; Daniela Rojas Castro; François Pichon; Bojan Cigan; Sophocles Chanos; Paula Meireles; Raquel Lucas; Stéphane Morel; Per Slaaen Kaye; Cristina Agustí; Irena Klavs; Tom Platteau; Jordi Casabona Journal: BMJ Open Date: 2016-07-13 Impact factor: 2.692
Authors: S Vaccher; A Grulich; J McAllister; D J Templeton; M Bloch; A McNulty; J Holden; I M Poynten; G Prestage; I Zablotska Journal: BMJ Open Date: 2016-06-20 Impact factor: 2.692
Authors: Stefanie J Vaccher; Andrew E Grulich; Bridget G Haire; Damian P Conway; Isobel M Poynten; Catriona Ooi; Rosalind Foster; David J Templeton; Iryna B Zablotska Journal: PLoS One Date: 2017-09-26 Impact factor: 3.240
Authors: Ellen White; David T Dunn; Monica Desai; Mitzy Gafos; Peter Kirwan; Ann K Sullivan; Amanda Clarke; Sheena McCormack Journal: Sex Transm Infect Date: 2019-03-27 Impact factor: 3.519
Authors: Kathleen E Ryan; Anne Mak; Mark Stoove; Brian Price; Christopher K Fairley; Simon Ruth; Luxshimi Lal; Jason Asselin; Carol El-Hayek; Long Nguyen; Colin Batrouney; David Wilson; John Lockwood; Dean Murphy; Vincent J Cornelisse; Norman Roth; Jeff Willcox; Christina C Chang; Judy Armishaw; Ban K Tee; Matthew Penn; George Forgan-Smith; Christopher Williams; Jeff Montgomery; Kat Byron; Alison Coelho; Brent Allen; Jeremy Wiggins; Jenny Kelsall; Olga Vujovic; Michael West; Anna B Pierce; Daniel Gallant; Charlotte Bell; John B F de Wit; Jennifer F Hoy; Steve L Wesselingh; Robert M Grant; Edwina J Wright Journal: Front Public Health Date: 2018-05-29
Authors: Vincent J Cornelisse; Christopher K Fairley; Mark Stoove; Jason Asselin; Eric P F Chow; Brian Price; Norman J Roth; Jeff Willcox; B K Tee; Matthew Penn; Christina C Chang; Judith Armishaw; George Forgan-Smith; Edwina J Wright Journal: Clin Infect Dis Date: 2018-11-28 Impact factor: 9.079